```html

The Pfizer Research Grant Request for Proposals is a competitive grant program aimed at enhancing antimicrobial stewardship and treatment optimization under antibiotics appropriate use policy in China. This initiative seeks to address critical clinical unmet needs in infection management, particularly in the context of recent advancements in immunosuppressive therapies that have improved patient survival but also increased the risk of infection complications.

Overview

Recent advancements in immunosuppressive therapies have significantly improved patient survival; however, these therapies are associated with increased risk of infection complications and influence the epidemiology of infectious diseases. Clinical infection management in China faces challenges such as poor risk factor identification, inappropriate empirical treatments, delayed initiation of targeted therapy, and suboptimal treatment duration. These issues contribute to increased mortality, longer hospital stays, and higher hospital costs. The ongoing healthcare reforms in China emphasize standardized care pathways and precise treatment strategies, making the optimization of therapeutic pathways essential for improving patient outcomes and supporting hospitals in meeting policy requirements.

Geographic Scope

The funding opportunity is specifically targeted at projects conducted in Mainland China. This geographic focus is crucial for addressing the unique challenges and needs of the healthcare system in this region, particularly in relation to antimicrobial stewardship and infection management.

Funding Range and Project Length

The estimated total available budget for this Request for Proposals (RFP) is $100,000, intended to support 5-6 research projects. Individual projects can request up to $20,000, with a maximum project length of 2 years. Projects must be completed no later than September 2028, with priority given to proposals that can be completed in a shorter timeframe.

Eligibility Criteria

To be eligible for this grant, the institution and Principal Investigator (PI) must be based in Mainland China. Only organizations, not individuals or medical practice groups, can receive grants. The PI must hold a medical or postdoctoral degree (MD, PhD, or equivalent), or an advanced nursing degree, and must be an employee or contractor of the requesting organization. It is essential for applicants to confirm their organization’s ability to accept funding directly from Pfizer Investment Co., Ltd. before submitting an application.

Submission Process and Key Dates

Applications must be submitted through the designated online portal. The submission deadline is 31 March 2026, with grant award notifications anticipated by 30 June 2026. Projects are expected to start by 30 September 2026 and must conclude by 30 September 2028. It is important to adhere to the submission guidelines to ensure that applications are accepted and reviewed.

Review and Approval Process

Grant requests will be reviewed by Pfizer to make final grant decisions. All applicants will be notified via email regarding the outcome of their applications. If a grant is approved, the institution will be required to enter into a written grant agreement with Pfizer. Modifications to grant agreements will not be reviewed unless a genuine conflict exists with applicable law.

About Pfizer Grants

Pfizer supports independent initiatives in the healthcare community aimed at improving patient outcomes in areas of unmet medical need. The competitive grant program involves a publicly posted general Request for Proposal (RFP) that outlines areas of interest, timelines for review, and an internal review process for final grant decisions. Organizations are invited to submit applications addressing the research gaps specified in the RFP.

```